One-Year Outcome of Aflibercept and Photodynamic Therapy in a Caucasian Patient with Polypoidal Choroidal Vasculopathy Refractory to Ranibizumab and Photodynamic Therapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
One-Year Outcome of Aflibercept and Photodynamic Therapy in a Caucasian Patient with Polypoidal Choroidal Vasculopathy Refractory to Ranibizumab and Photodynamic Therapy ; volume:9 ; number:1 ; year:2018 ; pages:172-178
Case reports in ophthalmology ; 9, Heft 1 (2018), 172-178
- Urheber
-
Medina-Baena, Marta
Huertos-Carrillo, María Jesús
Rodríguez, Laura
García-Pulido, Juan Ignacio
Cornejo-Castillo, Carlos
Calandria-Amiguetti, José María
- DOI
-
10.1159/000487227
- URN
-
urn:nbn:de:101:1-201805241951
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:22 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Medina-Baena, Marta
- Huertos-Carrillo, María Jesús
- Rodríguez, Laura
- García-Pulido, Juan Ignacio
- Cornejo-Castillo, Carlos
- Calandria-Amiguetti, José María
Ähnliche Objekte (12)
One-year outcome of combination therapy with intravitreal aflibercept and photodynamic therapy for polypoidal choroidal vasculopathy
1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy
Comparison of 3-year outcomes of photodynamic therapy combined with intravitreal ranibizumab or aflibercept for polypoidal choroidal vasculopathy in a European cohort
Cosmetic photodynamic therapy
Photodynamic antimicrobial therapy
Photodiagnosis and photodynamic therapy
Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen
Evaluating photodynamic therapy versus brolucizumab as a second-line treatment for polypoidal choroidal vasculopathy
Optic disk melanocytoma associated with polypoidal choroidal vasculopathy lesions, after combination treatment of photodynamic therapy and intavitreal aflibercept (Eylea), a case report
No-Dose Photodynamic Therapy Against Half-Dose Photodynamic Therapy for Treatment of Central Serous Chorioretinopathy
Photodynamic Therapy: Controllable Photodynamic Therapy Implemented by Regulating Singlet Oxygen Efficiency (Adv. Sci. 7/2017)
Advancements in photodiagnosis and photodynamic therapy
One-year outcome of combination therapy with intravitreal aflibercept and photodynamic therapy for polypoidal choroidal vasculopathy
1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy
Comparison of 3-year outcomes of photodynamic therapy combined with intravitreal ranibizumab or aflibercept for polypoidal choroidal vasculopathy in a European cohort
Cosmetic photodynamic therapy
Photodynamic antimicrobial therapy
Photodiagnosis and photodynamic therapy
Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen
Evaluating photodynamic therapy versus brolucizumab as a second-line treatment for polypoidal choroidal vasculopathy
Optic disk melanocytoma associated with polypoidal choroidal vasculopathy lesions, after combination treatment of photodynamic therapy and intavitreal aflibercept (Eylea), a case report
No-Dose Photodynamic Therapy Against Half-Dose Photodynamic Therapy for Treatment of Central Serous Chorioretinopathy
Photodynamic Therapy: Controllable Photodynamic Therapy Implemented by Regulating Singlet Oxygen Efficiency (Adv. Sci. 7/2017)
Advancements in photodiagnosis and photodynamic therapy
One-year outcome of combination therapy with intravitreal aflibercept and photodynamic therapy for polypoidal choroidal vasculopathy
1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy
Comparison of 3-year outcomes of photodynamic therapy combined with intravitreal ranibizumab or aflibercept for polypoidal choroidal vasculopathy in a European cohort
Cosmetic photodynamic therapy
Photodynamic antimicrobial therapy
Photodiagnosis and photodynamic therapy
Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen
Evaluating photodynamic therapy versus brolucizumab as a second-line treatment for polypoidal choroidal vasculopathy
Optic disk melanocytoma associated with polypoidal choroidal vasculopathy lesions, after combination treatment of photodynamic therapy and intavitreal aflibercept (Eylea), a case report
No-Dose Photodynamic Therapy Against Half-Dose Photodynamic Therapy for Treatment of Central Serous Chorioretinopathy
Photodynamic Therapy: Controllable Photodynamic Therapy Implemented by Regulating Singlet Oxygen Efficiency (Adv. Sci. 7/2017)